Merck, Inc.
🇵🇭Philippines
A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06733688
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLS) (MK-3475-01G/KEYMAKER U01)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06731907
A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06719544
A Study of the Effect of Itraconazole and Phenytoin on MK-1084 in Healthy Adults (MK-1084-008)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06719557
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06719570
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 350
- Registration Number
- NCT06721156
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1046
- Registration Number
- NCT06717347
A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06703463
- Locations
- 🇺🇸
Celerion (Site 0002), Lincoln, Nebraska, United States
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT06701305
- Locations
- 🇺🇸
QPS-MRA, LLC (Site 0001), South Miami, Florida, United States
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT06699329
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
© Copyright 2024. All Rights Reserved by MedPath